Search Results for "HIV"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for HIV. Results 61 to 70 of 181 total matches.
Drug Interactions
The Medical Letter on Drugs and Therapeutics • Jun 08, 2003 (Issue 1158)
of HIV protease inhibitors and many other drugs because it increases the synthesis of
CYP3A4. The herbal ...
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Immune Globulin IV for Prevention of RH Isoimmunization and for Treatment of ITP
The Medical Letter on Drugs and Therapeutics • Jan 19, 1996 (Issue 966)
,
including HIV-infected patients, as long as the patient is Rh-positive and has not had a splenectomy. About ...
immune globulin (human) has been available for many years in an intramuscular (IM) formulation for prevention of Rh isoimmunization in pregnant Rh-negative women (Medical Letter, 16:3, 1974). Recently, the US Food and Drug Administration (FDA) approved the first intravenous (IV) immune globulin preparation (WinRho SD - Univax), not only for preventing Rh isoimmunization, but also for treatment of immune thrombocytopenic purpura (ITP) in Rh-positive patients.
Sofosbuvir (Sovaldi) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Jan 20, 2014 (Issue 1434)
for 12 or 24 weeks was also
effective for treatment of HCV/HIV co-infection in
patients infected ...
The FDA has approved the nucleotide polymerase
inhibitor sofosbuvir (Sovaldi – Gilead) for use in
combination with other antiviral drugs for treatment of
chronic hepatitis C virus (HCV) infection.
Rifapentine--A Long-Acting Rifamycin for Tuberculosis
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999 (Issue 1047)
in 722 HIV-negative patients with pulmonary tuberculosis, described in the package insert, compared ...
Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.
Miconazole (Oravig) for Oropharyngeal Candidiasis
The Medical Letter on Drugs and Therapeutics • Nov 29, 2010 (Issue 1352)
, double-dummy trial in
patients with HIV and oropharyngeal candidiasis randomized
476 patients to 14 ...
The FDA has approved a buccal tablet formulation of
miconazole (Oravig – Strativa) for local treatment of
oropharyngeal candidiasis in adults. Miconazole has
been available for many years in topical formulations
for treatment of superficial fungal infections and vulvovaginal
candidiasis.
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
Not recommended
Other HIV regimens containing boosted tenofovir disoproxil fumarate Increased tenofovir serum ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175 doi:10.58347/tml.2024.1714f | Show Introduction Hide Introduction
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
inject drugs, HIV-infected men who
have unprotected sex with men, and men who have
sex with men ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
instead in patients with genotype 1 without cirrhosis, except those with HIV and those with HCV RNA ≥6 ...
View Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e174 doi:10.58347/tml.2024.1714e | Show Introduction Hide Introduction
Intravenous Immune Globulin
The Medical Letter on Drugs and Therapeutics • Dec 25, 1992 (Issue 886)
Med, 326:1123, 1992).
A controlled trial in children with HIV infection and CD4+ T-lymphocyte counts ...
Intravenous formulations of immune globulin (IVIG) have been available for more than ten years for treatment of immune deficiency (Medical Letter, 24:81, 1982). Seven preparations are now licensed in the USA, with additional indications for their use.